Nevanac

   
Google
 
Web NewDrugInformation.com

Nevanac


Drug - Nevanac
The trade name of the product as shown on the labeling.

Dosage - SUSPENSION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Nepafenac
Multiple ingredients are in alphabetical order.

Strength - 0.1%
The potency of the active ingredient(s), Nepafenac. May repeat for multiple part products.

Applicant - ALCON
The firm name holding legal responsibility for Nevanac. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 021862
The FDA assigned number to Nevanac. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Nevanac. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Aug 19, 2005
The date Nevanac was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Nevanac. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Nevanac is in. Format is RX, OTC, DISCN.

Applicant Full Name - Alcon Inc
The full name of the firm holding legal responsibility for the new application of Nevanac.

Nevanac